Navigation Links
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
Date:1/8/2014

hi Sankyo's impressive capabilities, global reach, and open, collaborative culture make them ideal partners," said Jake Reder, Ph.D., President and Chief Executive Officer of Celdara Medical. "The team at Celdara Medical is excited to work hand-in-hand with Daiichi Sankyo on some of the most challenging problems in human health."

About Daiichi Sankyo


The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information about Daiichi Sankyo, please visit www.daiichisankyo.com.   

About Virtici, LLC

Founded in 2011, Virtici is a privately held product-development company headquartered in Seattle, Washington. Virtici's mission is to improve quality of life and save lives, and is primarily developing products to improve the way we diagnose and treat cancer, autoimmunity, and cardiovascular/metabolic diseases. Virtici, working closely with our affiliate Celdara Medical, partners with inventors and their research institutions, bringing the business and finance expertise to accelerate product development. Working with its partners in the pharmaceutical industry, Virtici connects the entire product development lifecycle by improving innovation, enhancing discovery and increasing product development efficiencies. Fo
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
6. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
10. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
11. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 Symmetry Medical Inc. (NYSE: ... medical device solutions, including orthopedic implants, surgical instruments, ... it has signed a definitive agreement to acquire ... design, development and manufacturing of electrosurgical instruments and ...
... Aug. 3, 2011 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... were $111.2 million, a 17 percent increase over revenues ... Results for all periods of fiscal 2010 ...
Cached Medicine Technology:Symmetry Medical to Acquire Olsen Medical 2Symmetry Medical to Acquire Olsen Medical 3Thoratec Reports Second Quarter Revenue Increase of 17 Percent 2Thoratec Reports Second Quarter Revenue Increase of 17 Percent 3Thoratec Reports Second Quarter Revenue Increase of 17 Percent 4Thoratec Reports Second Quarter Revenue Increase of 17 Percent 5Thoratec Reports Second Quarter Revenue Increase of 17 Percent 6Thoratec Reports Second Quarter Revenue Increase of 17 Percent 7Thoratec Reports Second Quarter Revenue Increase of 17 Percent 8Thoratec Reports Second Quarter Revenue Increase of 17 Percent 9Thoratec Reports Second Quarter Revenue Increase of 17 Percent 10Thoratec Reports Second Quarter Revenue Increase of 17 Percent 11Thoratec Reports Second Quarter Revenue Increase of 17 Percent 12Thoratec Reports Second Quarter Revenue Increase of 17 Percent 13Thoratec Reports Second Quarter Revenue Increase of 17 Percent 14Thoratec Reports Second Quarter Revenue Increase of 17 Percent 15Thoratec Reports Second Quarter Revenue Increase of 17 Percent 16Thoratec Reports Second Quarter Revenue Increase of 17 Percent 17Thoratec Reports Second Quarter Revenue Increase of 17 Percent 18Thoratec Reports Second Quarter Revenue Increase of 17 Percent 19
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... A new type of sensor for people with diabetes is ... saliva instead of blood, researchers report. Scientists at Brown ... it using artificial saliva. It uses light, metal and a ... "Everybody knows that diabetics have to prick their fingers ...
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers ... released its new range of elegant Quinceanera dresses ... at discounted prices. Worldwide clients can enjoy this special ... company’s online shop, there are plenty of beautiful dresses ... great materials. MyDressCity.com’s hot items are prom gowns, bridesmaid ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
... Calif, Nov. 3 BioMarin Pharmaceutical,Inc. (Nasdaq: ... Morquio Clinical,Assessment Program (MorCAP) for patients with the ... Morquio A Syndrome. MorCAP is,designed to augment available ... function and other parameters in affected patients.,BioMarin expects ...
... Services Cited as Pivotal to ... Efficiency Statewide, NASHVILLE, Tenn., Nov. 3 Emdeon, ... for the healthcare industry,has been named the electronic data ... Association (MHA). Emdeon was selected,through a competitive bidding process ...
... Va., Nov. 3 "When my father was formally,diagnosed ... book,pamphlet, and newspaper article I could get my hands ... Conversation About Alzheimer,s" (published by,AuthorHouse -- http://www.authorhouse.com ). ... I told myself that once I knew the facts, ...
... its inaugural list of the top 100, ... a leading,provider of kidney care services for those ... named in the top 100 of Modern Healthcare,s,Best ... on the list, is,the only nationwide healthcare services ...
... Nov. 3 Sabin Robbins, a,75-year old prostate ... Florida to benefit from treatment with new RapidArc(TM),radiotherapy ... Cancer Center of Boynton Beach, Florida. RapidArc, which ... ), unleashes the precision of,intensity-modulated radiation therapy (IMRT) ...
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... novel anti-infective products, today,announced that it has ... VCG,& Associates will serve as MiddleBrook,s strategic ... pricing and reimbursement, contract,administration, national account management ...
Cached Medicine News:Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4Health News:Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange 2Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Modern Healthcare Names DaVita One of the Best Places to Work 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 3Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
Zero clearance, front breathing, undercounter refrigeration system....
Designed to meet the requirements of reagent grade water for routine analysis....
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: